Valuation: Natera, Inc.

Market Cap 57.76B 51.77B 48.2B 43.73B 82.48B 5,531B 83B 580B 227B 2,849B 217B 212B 9,160B P/E 2026 *
-283x
P/E 2027 * -5,385x
Enterprise Value 56.69B 50.81B 47.31B 42.92B 80.95B 5,429B 81.46B 569B 223B 2,796B 213B 208B 8,990B EV / Sales 2026 *
19.5x
EV / Sales 2027 * 16x
Free-Float
97.24%
Yield 2026 *
-
Yield 2027 * -
1 day-0.73%
1 week-6.55%
Current month-3.76%
1 month+20.93%
3 months+47.35%
6 months+106.07%
Current year+73.63%
1 week 380.39
Extreme 380.39
407.06
1 month 327.15
Extreme 327.1509
437.41
Current year 181
Extreme 181
437.41
1 year 170.82
Extreme 170.815
437.41
3 years 36.9
Extreme 36.9
437.41
5 years 26.1
Extreme 26.1
437.41
10 years 7.35
Extreme 7.35
437.41
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Sell

Chief Executive Officer

-1,273 0.0009%
10/1/26 Sell

Executive/Senior Manager

-3,000 0.0021%
9/23/26 Other

Founder

18,064 0.0125%
Change 5-day change 1-year change 3-year change Capi.($)
-0.73%-6.55%+134.99%+909.82% 57.76B
+1.83%+0.84%+12.63%+23.72% 110B
+1.66%+5.44%+10.47%+95.17% 97.66B
+1.84%-3.44%-11.21%+64.93% 26.71B
+0.72%+0.18%+26.38%+92.86% 25.49B
+1.08%+2.23%+13.55%+59.46% 25.32B
-0.92%-0.31%-18.30%-0.66% 21.21B
+1.89%+3.58%+41.77%+408.63% 21.24B
+0.44%+4.62%+14.98%+88.19% 20.02B
0.00%+1.80%-1.13%+32.55% 17.08B
Average +0.78%+1.97%+22.41%+177.47% 42.27B
Weighted average by Cap. +1.05%+1.65%+27.70%+191.75%

Financials

2026 *2027 *
Net sales 2.91B 2.61B 2.43B 2.2B 4.16B 279B 4.18B 29.2B 11.43B 144B 10.93B 10.69B 461B 3.52B 3.15B 2.93B 2.66B 5.02B 337B 5.05B 35.27B 13.8B 173B 13.2B 12.91B 557B
Net income -200M -179M -167M -151M -286M -19.15B -287M -2.01B -785M -9.86B -751M -734M -31.71B -1.89M -1.69M -1.58M -1.43M -2.7M -181M -2.71M -18.96M -7.42M -93.19M -7.09M -6.94M -300M
Net Debt -1.07B -960M -894M -811M -1.53B -103B -1.54B -10.75B -4.21B -52.85B -4.02B -3.93B -170B -1.36B -1.22B -1.14B -1.03B -1.95B -131B -1.96B -13.69B -5.36B -67.3B -5.12B -5.01B -216B
Projected Income Statement - Annual - Natera, Inc.
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-10-12 US$397.77 -0.73% 934,689
26-10-09 US$400.71 +2.54% 1,011,448
26-10-08 US$390.79 -1.21% 2,443,275
26-10-07 US$395.56 -1.27% 2,816,863
26-10-06 US$400.65 -5.87% 2,499,462
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Ratings Surperformance© - Natera, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
400.71USD
Average target price
387.52USD
Spread / Average Target
-3.29%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Natera, Inc.
  1. Stock Market
  2. Stocks
  3. NTRA Stock